NEW YORK, July 8, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Incyte Corporation (NASDAQ: INCY), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Arrowhead Research Corp. (NASDAQ: ARWR), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Techne Corp. (NASDAQ: TECH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4525-100free.

-- Incyte Corporation Analyst Notes On July 3, 2014, Incyte Corp.'s (Incyte) stock went down slightly by 0.29% to end the day at $55.62 compared to the previous day's closing price of $55.78. The Company's stock increased 8.16% during the past three trading months compared to the Nasdaq Composite which rose 5.86% during the same trading period. The full analyst notes on Incyte are available to download free of charge at:

http://www.analystsreview.com/Jul-08-2014/INCY/report.pdf

-- BioMarin Pharmaceutical Inc. Analyst Notes On July 3, 2014, BioMarin Pharmaceutical Inc. (BioMarin) stock increased 0.48% to end the day at $64.59 compared to the previous day's closing price of $64.28. The Company's stock gained 3.83% over the past three trading days compared to the Nasdaq Composite which rose 1.76% during the same trading period. The full analyst notes on BioMarin are available to download free of charge at:

http://www.analystsreview.com/Jul-08-2014/BMRN/report.pdf

-- Arrowhead Research Corp. Analyst Notes On July 3, 2014, Arrowhead Research Corp. (Arrowhead) stock increased 1.23% to end the day at $13.18 compared to the previous day' closing price of $13.02. The Company's stock increased 2.33% over the past one trading month compared to the Nasdaq Composite which rose 5.95% during the same trading period. The full analyst notes on Arrowhead are available to download free of charge at:

http://www.analystsreview.com/Jul-08-2014/ARWR/report.pdf

-- Ligand Pharmaceuticals Incorporated Analyst Notes On June 24, 2014, Ligand Pharmaceuticals Inc. (Ligand) announced that it has signed a global license agreement with TG Therapeutics, Inc. to develop and commercialize Ligand's Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors. The Company stated that the IRAK-4 program is in preclinical development for potential use in certain cancers and autoimmune diseases. Under the agreement, Ligand is entitled to receive 125,000 shares of TG Therapeutics common stock, valued at c.$1 million at date of signing, as well as $207 million in potential milestone payments. Ligand added that is also eligible to receive tiered royalties of 6% to 9.5% on future net sales of licensed products containing patented IRAK-4 inhibitors. The full analyst notes on Ligand are available to download free of charge at:

http://www.analystsreview.com/Jul-08-2014/LGND/report.pdf

-- Techne Corp. Analyst Notes On July 2, 2014, Techne Corp. (Bio-Techne) announced its acquisition of Novus Biologicals, a Colorado-based supplier of a large portfolio of both outsourced and in-house developed antibodies and other reagents for life science research, for $60 million in cash. Charles R. Kummeth, President and CEO of Bio-Techne, commented, "This acquisition is consistent with our mission to expand our products offering and ensure that our customers are being served in the most complete fashion with the best quality reagents. We are eager to adopt the digital commercial platforms that Novus Biologicals has perfected over the years to accelerate the growth of our overall business." The full analyst notes on Techne are available to download free of charge at:

http://www.analystsreview.com/Jul-08-2014/TECH/report.pdf

-- About Analysts Review We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

=============== EDITOR'S NOTES: ===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Analysts Review